Skip to content
10-Q

Quarterly Report

ARS Pharmaceuticals, Inc. SPRY

0000950170-25-070900

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 98.21M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $235.86M
Short Term Investments Q1 2025 · Dec 31, 2024 $263.21M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $39.86M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $50.82M
Current Liabilities Q1 2025 · Mar 31, 2025 $27.62M
Current Liabilities Q1 2025 · Dec 31, 2024 $23.44M
Total Liabilities Q1 2025 · Mar 31, 2025 $98.34M
Total Liabilities Q1 2025 · Dec 31, 2024 $94.36M
Current Assets Q1 2025 · Mar 31, 2025 $303.86M
Current Assets Q1 2025 · Dec 31, 2024 $334.3M
Total Assets Q1 2025 · Mar 31, 2025 $327.32M
Total Assets Q1 2025 · Dec 31, 2024 $351.15M
Shares Diluted Q1 2025 · Mar 31, 2024 96.49M sh
Capex Q1 2025 · Mar 31, 2024 $83K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$6.71M
Stockholders Equity Q1 2025 · Mar 31, 2024 $223.87M
Stockholders Equity Q1 2025 · Dec 31, 2023 $230.76M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.11
Eps Basic Q1 2025 · Mar 31, 2024 −$0.11
Sga Expense restated Q1 2025 · Mar 31, 2024 $7.96M
Rd Expense Q1 2025 · Mar 31, 2024 $5.23M
Net Income Q1 2025 · Mar 31, 2024 −$10.29M
Operating Income Q1 2025 · Mar 31, 2024 −$13.19M
Revenue Q1 2025 · Mar 31, 2024 $0